Latest Evidence for Treating Secondary AML

Latest Evidence for Treating Secondary AML

For patients with secondary acute myeloid leukemia (sAML), novel treatment delivery technologies offer the potential to safely administer chemotherapy agents and achieve durable responses in this higher-risk population. As real-world evidence emerges for the treatment of sAML, it is critical that providers are up to date with these updates to make individualized, guideline-aligned treatment decisions. Are you up for the challenge? Test your knowledge on the latest clinical data and different treatment options for sAML with this bite-sized booster quiz.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/online/latest-evidence-treating-secondary-aml
  • Start Date: 2024-05-10 05:00:00
  • End Date: 2024-05-10 05:00:00
  • Credit Details: AAPA Category 1 Credit™️: 0.25 hours
    AMA PRA Category 1 Credit™️: 0.25 hours
    Nursing: 0.25 hours
    Pharmacy: 0.25 hours
  • MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: Source: Jazz Pharmaceuticals, Inc. - Amount: 33166.67 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Hematology, Medical Oncology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.